Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Saved in:
| Title: | Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. |
|---|---|
| Authors: | Shah A; Modelling and Simulation, Evidera, Waltham, MA, USA., Tosh JC; Modelling and Simulation, Evidera, London, UK., Ambavane A; Modelling and Simulation, Evidera, London, UK., Nikolaou A; Modelling and Simulation, Evidera, London, UK., Hogea C; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA., Samyshkin Y; Value Evidence and Outcomes, GlaxoSmithKline, Brentford, UK., Gorsh B; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA., Maiese EM; Value Evidence and Outcomes, GlaxoSmithKline, Philadelphia, PA, USA., Wang F; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA. |
| Source: | ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2021 Sep 10; Vol. 13, pp. 789-800. Date of Electronic Publication: 2021 Sep 10 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101560564 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6981 (Print) Linking ISSN: 11786981 NLM ISO Abbreviation: Clinicoecon Outcomes Res Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1178-6981 |
|---|---|
| DOI: | 10.2147/CEOR.S310619 |
